Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Oxford BioMedica
Oxford BioMedica
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
OINDPs: Nosey about recent developments?
OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Compact process thermostat for efficient temperature control in the laboratory
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
AviadoBio expands presence at Canary Wharf
The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Pharmaceutical
UK vaccine manufacturing nonprofit signs first industry partnership
Oxford Biomedica will be collaborating with VMIC to enable scaled-up manufacture of viral vector-based vaccines
Hi Tech Manufacturing
Oxford Biomedica partners with Microsoft to improve yield of gene therapy via machine learning
Collaboration will see the computing expert develop in silico models and algorithms to address the manufacturing challenges of novel therapies
Recruitment
CGT Catapult addresses skills gap with apprenticeship programme for advanced therapies
Programme will address the projected skills shortage facing public and private employers in the growing cell and gene therapy sector
Design & Build
Oxford BioMedica receives MHRA GMP manufacturing approvals
For lentiviral gene therapy bioprocessing and process development
Design & Build
WHP completes bio-manufacturing facility for Oxford BioMedica
Additional cleanroom space took less than 12 months from concept to completion and creates extra capacity
Manufacturing
Dr Paul Blake becomes Chief Development Officer at Oxford BioMedica
Will take responsibility for the clinical development of pipeline of gene and cell therapies
Research & Development
UK biotechs win Biomedical Catalyst funding of almost £100m
Thirty-three UK companies have received business-led awards
Subscribe now